On July 16, 2024, Endo USA, Inc. voluntarily recalled a single lot of Clonazepam 0.125 mg and 0.25 mg Orally Disintegrating tablets (ODT) due to a packaging error. Some of the 60-pack cartons were labeled as containing Clonazepam 0.125mg ODT when they may contain the higher dose Clonazepam 0.25mg ODT. The blister strips inside the product pack did reflect the correct strength of 0.25 mg.
The recalled lot number is USP (C-IV) Lot Number 550147301.The product lot was distributed through wholesale distributors to retail pharmacies nationwide. Click here for more details about the medication recall.
Clonazepam is a benzodiazepine used to treat panic disorder or certain types of seizures. Taking a higher dose than intended may lead to adverse effects such as drowsiness, confusion, slow muscle reactions, sleepiness and loss in muscle tone. There are also significant - possibly life-threatening - risks for patients with concomitant pulmonary disease, patients prescribed near maximal dosing, and patients taking other medications that could cause respiratory depression.
To date, Endo, a diversified specialty pharmaceutical company headquartered in Malvern, Pennsylvania, has not received any reports of adverse events associated with this product lot recall. They recommend that any patient in possession of any unused prescribed 60 tablet cartons of the recalled medications should discontinue use of the product.
MyMatrixx Actions
MyMatrixx transaction records indicate that scripts for both Clonazepam 0.125 mg and 0.25 mg Orally Disintegrating tablets (ODT) are low for our book of business. We do echo the Endo recommendation to discontinue use of the product. If you have any questions about this recall, please contact your MyMatrixx account team.